Haneder Stefan, Giordano Frank A, Konstandin Simon, Brehmer Stefanie, Buesing Karen A, Schmiedek Peter, Schad Lothar R, Wenz Frederik, Schoenberg Stefan O, Ong Melissa M
Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Neuroradiology. 2015 Mar;57(3):321-6. doi: 10.1007/s00234-014-1468-2. Epub 2014 Nov 27.
We report the first case of an intraoperative radiotherapy (IORT) in a patient with recurrent glioblastoma multiforme (GBM) who was followed up with a novel magnetic resonance imaging (MRI) method-(23)Na-MRI-in comparison to a standard contrast-enhanced (1)H-MRI and (18)F-FET-PET.
A 56-year-old female patient with diagnosed GBM in July 2012 underwent tumor resection, radiochemotherapy, and three cycles of chemotherapy. After a relapse, 6 months after the initial diagnosis, an IORT was recommended which was performed in March 2013 using the INTRABEAM system (Carl Zeiss Meditec AG, Germany) with a 3-cm applicator and a surface dose of 20 Gy. Early post-operative contrast-enhanced and 1-month follow-up (1)H-MRI and a (18)F-FET-PET were performed. In addition, an IRB-approved (23)Na-MRI was performed on a 3.0-T MR scanner (MAGNETOM TimTrio, Siemens Healthcare, Germany).
After re-surgery and IORT in March 2013, only a faint contrast enhancement but considerable surrounding edema was visible at the medio-posterior resection margins. In April 2013, new and progressive contrast enhancement, edema, (23)Na content, and increased uptake in the (18)F-FET-PET were visible, indicating tumor recurrence. Increased sodium content within the area of contrast enhancement was found in the (23)Na-MRI, but also exceeding this area, very similar to the increased uptake depicted in the (18)F-FET-PET. The clearly delineable zone of edema in both examinations exhibits a lower (23)Na content compared to areas with suspected proliferating tumor tissue.
(23)Na-MRI provided similar information in the suspicious area compared to (18)F-FET-PET, exceeding conventional (1)H-MRI. Still, (23)Na-MRI remains an investigational technique, which is worth to be further evaluated.
我们报告了首例复发性多形性胶质母细胞瘤(GBM)患者术中放疗(IORT)的病例,并采用一种新型磁共振成像(MRI)方法——(23)Na-MRI对其进行随访,同时与标准的对比增强(1)H-MRI和(18)F-FET-PET进行比较。
一名56岁女性患者于2012年7月被诊断为GBM,接受了肿瘤切除、放化疗以及三个周期的化疗。在初始诊断6个月后复发,建议进行IORT,于2013年3月使用INTRABEAM系统(德国卡尔蔡司医疗技术公司),采用3厘米的施源器,表面剂量为20 Gy。术后早期进行了对比增强和1个月随访的(1)H-MRI以及(18)F-FET-PET检查。此外,在一台3.0-T磁共振扫描仪(德国西门子医疗的MAGNETOM TimTrio)上进行了经机构审查委员会批准的(23)Na-MRI检查。
2013年3月再次手术并进行IORT后,在中后切除边缘仅可见微弱的对比增强,但周围有明显水肿。2013年4月,可见新的、进行性的对比增强、水肿、(23)Na含量以及(18)F-FET-PET摄取增加,提示肿瘤复发。在(23)Na-MRI中,对比增强区域内钠含量增加,但也超出了该区域,这与(18)F-FET-PET中显示的摄取增加非常相似。在两项检查中,清晰可辨的水肿区域与疑似肿瘤增殖组织区域相比,(23)Na含量较低。
与(18)F-FET-PET相比,(23)Na-MRI在可疑区域提供了类似的信息,优于传统的(1)H-MRI。不过,(23)Na-MRI仍是一种研究性技术,值得进一步评估。